: Prot #78934804CRD2001: A Phase 2b Randomized, Double‐blind, Active‐ and Placebo‐controlled, Parallel‐ group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Partici

Project: Research project

Project Details

StatusActive
Effective start/end date6/12/23 → 8/24/28

Funding

  • Parexel (Prot #78934804CRD2001 Amnd 1 // Prot #78934804CRD2001 Amnd 1)
  • Janssen Research & Development, LLC (Prot #78934804CRD2001 Amnd 1 // Prot #78934804CRD2001 Amnd 1)